The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).
 
Thomas G. Martin
Consulting or Advisory Role - TeneoBio
Research Funding - AMGEN (Inst); Genentech/Roche (Inst); Sanofi (Inst)
 
Meletios A. Dimopoulos
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Genesis Pharmaceuticals; Janssen-Cilag; Novartis; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Takeda
Research Funding - Amgen (Inst); Janssen-Cilag (Inst)
Travel, Accommodations, Expenses - Amgen; Genesis Pharmaceuticals; Janssen-Ortho
 
Kwee Yong
Speakers' Bureau - Amgen; Takeda
Research Funding - Amgen; Sanofi
 
Joseph Mikhael
Research Funding - Abbvie (Inst); Celgene (Inst); Sanofi (Inst)
 
Marie-Laure Risse
Employment - Sanofi
 
Gaëlle Asset
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Philippe Moreau
Honoraria - Amgen; Celgene; Janssen-Cilag; Novartis; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda